Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 772

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 3
Chunk 772
---
042 — Change in fair value of contingent consideration(850)15,060 2,377 Amortization of acquired intangible assets18,006 6,157 — Total operating expense 511,595 387,247 356,231 Operating loss (474,313)(334,467)(307,196)Loss on extinguishment of debt— (2,033)— Gain on debt restructuring154,407 — — Interest expense (13,412)(14,343)(14,690)Other income, net 23,783 32,684 7,638 Loss before income taxes(309,535)(318,159)(314,248)Income tax provision (benefit)316 (11,424)— Net loss(309,851)(306,735)(314,248)Other comprehensive income (loss):Unrealized gain (loss) on investments 203 4,984 (3,678)Comprehensive loss$(309,648)$(301,751)$(317,926)Net loss per share:Basic $(1.13)$(1.21)$(1.40)Diluted $(1.59)$(1.21)$(1.40)Weighted average shares outstanding used in calculating net loss per shareBasic 274,488 253,629 224,550 Diluted 288,366 253,629 224,550 

See accompanying notes to the consolidated financial statements.

Fiscal 2024 Form 10-K86

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 Common Stock Additional Paid-inCapitalAccumulatedOtherComprehensive Income (Loss)Accumulated DeficitTotalStockholders'Equity(in thousands)SharesAmountBalance at December 31, 2021220,978$221 $2,009,945 $(1,087)$(1,218,092)$790,987 Net loss—— — — (314,248)(314,248)Other comprehensive loss—— — (3,678)— (3,678)Issuance of common stock in conjunction with equity plans5,5276 11,224 — — 11,230 Share-based compensation expense—— 78,613 — — 78,613 Balance at December 31, 202